市場調査レポート

商品コード

1139948

ライソゾーム病治療市場：疾患タイプ別、治療タイプ別、エンドユーザー別：世界の機会分析および産業予測、2021-2031年

Lysosomal Disease Treatment Market By Disease Type, By Type of Therapy, By End User : Global Opportunity Analysis and Industry Forecast, 2021-2031

出版日: 2022年07月01日 | 発行: Allied Market Research

| ページ情報: 英文 319 Pages | 納期: 2～3営業日

価格

Cloud Access (Single User License)

USD 3,840 603,417円

レポートのクラウドアクセスでご利用頂けるライセンスです。ウェブポータルで配信され、60日間レポートにアクセスできます。この期間を過ぎるとレポートへのアクセスは失効します。コンテンツのダウンロード、印刷、共有、コピー＆ペーストはできません。

PDF (Business License)

USD 6,090 956,982円

レポートPDFをご利用いただけるライセンスです。ライセンスを付与されたPCでのみレポートPDFの保存、表示、利用が可能です。PDFl内のテキスト等のコピー＆ペーストは可能です。印刷は5回可能です。追加料金を支払うことで、2～5ユーザーを収容できるようにアップグレードできます。

PDF (Enterprise User License) & Excel (Data Pack) & Free Update

USD 10,500 1,649,970円

レポートPDFとExcel定量データをひとつの企業、及びその子会社でご利用頂けるライセンスです。ライセンスを付与されたPCでのみレポートPDFとExcelの保存、表示、利用が可能です。PDFとExcel内のテキスト等のコピー＆ペーストは可能です。PDFとExcelの印刷回数の制限はありません。印刷したレポートの利用は企業、及びその子会社内にて共有可能です。無料でレポートのアップデートがご利用いただけます。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=157.14円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

ライソゾーム病治療の世界市場は、2021年に75億7297万米ドル、2031年には140億9039万米ドルに達すると予測され、2022年から2031年にかけてCAGRは6.4%で成長すると予測しています。

ライソゾーム病は、ライソゾーム酸性リパーゼ酵素の欠乏または欠損によって引き起こされます。この酵素の欠乏により、リソソームの構造異常が生じ、体内の細胞内に様々な有害物質が蓄積されます。ライソゾーム病は約50種類あり、心臓、脳、皮膚、骨格、中枢神経系など様々な臓器に害を及ぼす可能性があります。さらに多くのライソゾーム病が発見され続けています。現在、いくつかのライソゾーム病の治療法の臨床試験が進行中ですが、多くのライソゾーム病は現在承認された治療法がありません。

ライソゾーム病として知られる一連の遺伝性代謝疾患は、さまざまな体細胞における酵素の欠損によって引き起こされます。ライソゾーム病治療市場の世界の成長の主な要因は、ライソゾーム病を治療する希少薬開発に対する認識と財政的インセンティブの増加による診断率の上昇です。また、ライソゾーム病の有病率の上昇、手頃な価格の製品コスト、ライソゾーム病を治療するための新規薬剤の開発に対する製薬会社の増加も、市場の成長の要因となっています。ライソゾーム病の治療法の欠如と治療費の高騰は、市場の成長を抑制する要因となっています。

概要
- 市場規模および予測
ゴーシェ病
- 主な市場動向、成長要因、機会
- 市場規模・予測：地域別
- 市場分析：国別
ファブリー病
- 主な市場動向、成長要因、機会
- 市場規模・予測：地域別
- 市場分析：国別
ポンペ症候群
- 主な市場動向、成長要因、機会
- 市場規模・予測：地域別
- 市場分析：国別
ムコ多糖症
- 主な市場動向、成長要因、機会
- 市場規模・予測：地域別
- 市場分析：国別
その他
- 主な市場動向、成長要因、機会
- 市場規模・予測：地域別
- 市場分析：国別

第5章ライソゾーム病治療市場：治療法タイプ別

概要
- 市場規模および予測
酵素補充療法
- 主な市場動向、成長要因、機会
- 市場規模・予測：地域別
- 市場分析：国別
幹細胞療法
- 主な市場動向、成長要因、機会
- 市場規模・予測：地域別
- 市場分析：国別
基質削減療法
- 主な市場動向、成長要因、機会
- 市場規模・予測：地域別
- 市場分析：国別
その他
- 主な市場動向、成長要因、機会
- 市場規模・予測：地域別
- 市場分析：国別

第6章ライソゾーム病治療市場：エンドユーザー別

概要
- 市場規模・予測
病院
- 主な市場動向、成長要因と機会
- 市場規模・予測：地域別
- 市場分析：国別
診療所
- 主な市場動向、成長要因、機会
- 市場規模・予測：地域別
- 市場分析：国別
その他
- 主な市場動向、成長要因、機会
- 市場規模・予測：地域別
- 市場分析：国別

第7章ライソゾーム病治療市場：地域別

概要
- 市場規模・予測
北米
- 主な動向と機会
- 北米市場規模・予測：疾患タイプ別
- 北米市場規模・予測：治療法タイプ別
- 北米市場規模・予測：エンドユーザー別
- 北米市場規模・予測：国別
  - 米国
  - カナダ
  - メキシコ
欧州
- 主な動向と機会
- 欧州市場規模・予測：疾患タイプ別
- 欧州市場規模・予測：治療法タイプ別
- 欧州市場規模・予測：エンドユーザー別
- 欧州市場規模・予測：国別
  - ドイツ
  - フランス
  - 英国
  - イタリア
  - スペイン
  - その他の欧州地域
アジア太平洋地域
- 主な動向と機会
- アジア太平洋地域の市場規模・予測：疾患タイプ別
- アジア太平洋地域の市場規模・予測：治療法タイプ別
- アジア太平洋地域の市場規模・予測：エンドユーザー別
- アジア太平洋地域の市場規模・予測：国別
  - 日本
  - 中国
  - オーストラリア
  - インド
  - 韓国
  - その他アジア太平洋地域
LAMEA
- 主な動向と機会
- LAMEAの市場規模・予測：疾患タイプ別
- LAMEAの市場規模・予測：治療法タイプ別
- LAMEAの市場規模・予測：エンドユーザー別
- LAMEAの市場規模・予測：国別
  - ブラジル
  - サウジアラビア
  - 南アフリカ共和国
  - LAMEAの残りの地域

第8章企業情勢

イントロダクション
主要成功戦略
主要10社の製品マッピング
競合ダッシュボード
競合のヒートマップ
主な発展

第9章企業プロファイル

Amicus Therapeutics, Inc.
Alexion Pharmaceuticals, Inc
BioMarin
Johnson & Johnson
Novartis AG
Pfizer Inc.
Sanofi
Takeda Pharmaceutical Company Limited
Eli Lilly and Company
Sigilon Therapeutics, Inc

図表

LIST OF TABLES

TABLE 1. GLOBAL LYSOSOMAL DISEASE TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 2. LYSOSOMAL DISEASE TREATMENT MARKET SIZE, FOR GAUCHER'S DISEASES, BY REGION, 2021-2031 ($MILLION)
TABLE 3. LYSOSOMAL DISEASE TREATMENT MARKET FOR GAUCHER'S DISEASES BY COUNTRY, 2021-2031 ($MILLION)
TABLE 4. LYSOSOMAL DISEASE TREATMENT MARKET SIZE, FOR FABRY DISEASES, BY REGION, 2021-2031 ($MILLION)
TABLE 5. LYSOSOMAL DISEASE TREATMENT MARKET FOR FABRY DISEASES BY COUNTRY, 2021-2031 ($MILLION)
TABLE 6. LYSOSOMAL DISEASE TREATMENT MARKET SIZE, FOR POMPE'S SYNDROME, BY REGION, 2021-2031 ($MILLION)
TABLE 7. LYSOSOMAL DISEASE TREATMENT MARKET FOR POMPE'S SYNDROME BY COUNTRY, 2021-2031 ($MILLION)
TABLE 8. LYSOSOMAL DISEASE TREATMENT MARKET SIZE, FOR MUCOPOLYSACCHARIDOSIS, BY REGION, 2021-2031 ($MILLION)
TABLE 9. LYSOSOMAL DISEASE TREATMENT MARKET FOR MUCOPOLYSACCHARIDOSIS BY COUNTRY, 2021-2031 ($MILLION)
TABLE 10. LYSOSOMAL DISEASE TREATMENT MARKET SIZE, FOR OTHERS, BY REGION, 2021-2031 ($MILLION)
TABLE 11. LYSOSOMAL DISEASE TREATMENT MARKET FOR OTHERS BY COUNTRY, 2021-2031 ($MILLION)
TABLE 12. GLOBAL LYSOSOMAL DISEASE TREATMENT MARKET, BY TYPE OF THERAPY, 2021-2031 ($MILLION)
TABLE 13. LYSOSOMAL DISEASE TREATMENT MARKET SIZE, FOR ENZYME REPLACEMENT THERAPY, BY REGION, 2021-2031 ($MILLION)
TABLE 14. LYSOSOMAL DISEASE TREATMENT MARKET FOR ENZYME REPLACEMENT THERAPY BY COUNTRY, 2021-2031 ($MILLION)
TABLE 15. LYSOSOMAL DISEASE TREATMENT MARKET SIZE, FOR STEM CELL THERAPY, BY REGION, 2021-2031 ($MILLION)
TABLE 16. LYSOSOMAL DISEASE TREATMENT MARKET FOR STEM CELL THERAPY BY COUNTRY, 2021-2031 ($MILLION)
TABLE 17. LYSOSOMAL DISEASE TREATMENT MARKET SIZE, FOR SUBSTRATE REDUCTION THERAPY, BY REGION, 2021-2031 ($MILLION)
TABLE 18. LYSOSOMAL DISEASE TREATMENT MARKET FOR SUBSTRATE REDUCTION THERAPY BY COUNTRY, 2021-2031 ($MILLION)
TABLE 19. LYSOSOMAL DISEASE TREATMENT MARKET SIZE, FOR OTHERS, BY REGION, 2021-2031 ($MILLION)
TABLE 20. LYSOSOMAL DISEASE TREATMENT MARKET FOR OTHERS BY COUNTRY, 2021-2031 ($MILLION)
TABLE 21. GLOBAL LYSOSOMAL DISEASE TREATMENT MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 22. LYSOSOMAL DISEASE TREATMENT MARKET SIZE, FOR HOSPITALS, BY REGION, 2021-2031 ($MILLION)
TABLE 23. LYSOSOMAL DISEASE TREATMENT MARKET FOR HOSPITALS BY COUNTRY, 2021-2031 ($MILLION)
TABLE 24. LYSOSOMAL DISEASE TREATMENT MARKET SIZE, FOR CLINICS, BY REGION, 2021-2031 ($MILLION)
TABLE 25. LYSOSOMAL DISEASE TREATMENT MARKET FOR CLINICS BY COUNTRY, 2021-2031 ($MILLION)
TABLE 26. LYSOSOMAL DISEASE TREATMENT MARKET SIZE, FOR OTHERS, BY REGION, 2021-2031 ($MILLION)
TABLE 27. LYSOSOMAL DISEASE TREATMENT MARKET FOR OTHERS BY COUNTRY, 2021-2031 ($MILLION)
TABLE 28. LYSOSOMAL DISEASE TREATMENT MARKET, BY REGION, 2021-2031 ($MILLION)
TABLE 29. NORTH AMERICA LYSOSOMAL DISEASE TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 30. NORTH AMERICA LYSOSOMAL DISEASE TREATMENT MARKET, BY TYPE OF THERAPY, 2021-2031 ($MILLION)
TABLE 31. NORTH AMERICA LYSOSOMAL DISEASE TREATMENT MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 32. NORTH AMERICA LYSOSOMAL DISEASE TREATMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 33. U.S. LYSOSOMAL DISEASE TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 34. U.S. LYSOSOMAL DISEASE TREATMENT MARKET, BY TYPE OF THERAPY, 2021-2031 ($MILLION)
TABLE 35. U.S. LYSOSOMAL DISEASE TREATMENT MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 36. CANADA LYSOSOMAL DISEASE TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 37. CANADA LYSOSOMAL DISEASE TREATMENT MARKET, BY TYPE OF THERAPY, 2021-2031 ($MILLION)
TABLE 38. CANADA LYSOSOMAL DISEASE TREATMENT MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 39. MEXICO LYSOSOMAL DISEASE TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 40. MEXICO LYSOSOMAL DISEASE TREATMENT MARKET, BY TYPE OF THERAPY, 2021-2031 ($MILLION)
TABLE 41. MEXICO LYSOSOMAL DISEASE TREATMENT MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 42. EUROPE LYSOSOMAL DISEASE TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 43. EUROPE LYSOSOMAL DISEASE TREATMENT MARKET, BY TYPE OF THERAPY, 2021-2031 ($MILLION)
TABLE 44. EUROPE LYSOSOMAL DISEASE TREATMENT MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 45. EUROPE LYSOSOMAL DISEASE TREATMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 46. GERMANY LYSOSOMAL DISEASE TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 47. GERMANY LYSOSOMAL DISEASE TREATMENT MARKET, BY TYPE OF THERAPY, 2021-2031 ($MILLION)
TABLE 48. GERMANY LYSOSOMAL DISEASE TREATMENT MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 49. FRANCE LYSOSOMAL DISEASE TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 50. FRANCE LYSOSOMAL DISEASE TREATMENT MARKET, BY TYPE OF THERAPY, 2021-2031 ($MILLION)
TABLE 51. FRANCE LYSOSOMAL DISEASE TREATMENT MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 52. U.K. LYSOSOMAL DISEASE TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 53. U.K. LYSOSOMAL DISEASE TREATMENT MARKET, BY TYPE OF THERAPY, 2021-2031 ($MILLION)
TABLE 54. U.K. LYSOSOMAL DISEASE TREATMENT MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 55. ITALY LYSOSOMAL DISEASE TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 56. ITALY LYSOSOMAL DISEASE TREATMENT MARKET, BY TYPE OF THERAPY, 2021-2031 ($MILLION)
TABLE 57. ITALY LYSOSOMAL DISEASE TREATMENT MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 58. SPAIN LYSOSOMAL DISEASE TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 59. SPAIN LYSOSOMAL DISEASE TREATMENT MARKET, BY TYPE OF THERAPY, 2021-2031 ($MILLION)
TABLE 60. SPAIN LYSOSOMAL DISEASE TREATMENT MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 61. REST OF EUROPE LYSOSOMAL DISEASE TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 62. REST OF EUROPE LYSOSOMAL DISEASE TREATMENT MARKET, BY TYPE OF THERAPY, 2021-2031 ($MILLION)
TABLE 63. REST OF EUROPE LYSOSOMAL DISEASE TREATMENT MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 64. ASIA-PACIFIC LYSOSOMAL DISEASE TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 65. ASIA-PACIFIC LYSOSOMAL DISEASE TREATMENT MARKET, BY TYPE OF THERAPY, 2021-2031 ($MILLION)
TABLE 66. ASIA-PACIFIC LYSOSOMAL DISEASE TREATMENT MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 67. ASIA-PACIFIC LYSOSOMAL DISEASE TREATMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 68. JAPAN LYSOSOMAL DISEASE TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 69. JAPAN LYSOSOMAL DISEASE TREATMENT MARKET, BY TYPE OF THERAPY, 2021-2031 ($MILLION)
TABLE 70. JAPAN LYSOSOMAL DISEASE TREATMENT MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 71. CHINA LYSOSOMAL DISEASE TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 72. CHINA LYSOSOMAL DISEASE TREATMENT MARKET, BY TYPE OF THERAPY, 2021-2031 ($MILLION)
TABLE 73. CHINA LYSOSOMAL DISEASE TREATMENT MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 74. AUSTRALIA LYSOSOMAL DISEASE TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 75. AUSTRALIA LYSOSOMAL DISEASE TREATMENT MARKET, BY TYPE OF THERAPY, 2021-2031 ($MILLION)
TABLE 76. AUSTRALIA LYSOSOMAL DISEASE TREATMENT MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 77. INDIA LYSOSOMAL DISEASE TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 78. INDIA LYSOSOMAL DISEASE TREATMENT MARKET, BY TYPE OF THERAPY, 2021-2031 ($MILLION)
TABLE 79. INDIA LYSOSOMAL DISEASE TREATMENT MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 80. SOUTH KOREA LYSOSOMAL DISEASE TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 81. SOUTH KOREA LYSOSOMAL DISEASE TREATMENT MARKET, BY TYPE OF THERAPY, 2021-2031 ($MILLION)
TABLE 82. SOUTH KOREA LYSOSOMAL DISEASE TREATMENT MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 83. REST OF ASIA-PACIFIC LYSOSOMAL DISEASE TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 84. REST OF ASIA-PACIFIC LYSOSOMAL DISEASE TREATMENT MARKET, BY TYPE OF THERAPY, 2021-2031 ($MILLION)
TABLE 85. REST OF ASIA-PACIFIC LYSOSOMAL DISEASE TREATMENT MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 86. LAMEA LYSOSOMAL DISEASE TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 87. LAMEA LYSOSOMAL DISEASE TREATMENT MARKET, BY TYPE OF THERAPY, 2021-2031 ($MILLION)
TABLE 88. LAMEA LYSOSOMAL DISEASE TREATMENT MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 89. LAMEA LYSOSOMAL DISEASE TREATMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 90. BRAZIL LYSOSOMAL DISEASE TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 91. BRAZIL LYSOSOMAL DISEASE TREATMENT MARKET, BY TYPE OF THERAPY, 2021-2031 ($MILLION)
TABLE 92. BRAZIL LYSOSOMAL DISEASE TREATMENT MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 93. SAUDI ARABIA LYSOSOMAL DISEASE TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 94. SAUDI ARABIA LYSOSOMAL DISEASE TREATMENT MARKET, BY TYPE OF THERAPY, 2021-2031 ($MILLION)
TABLE 95. SAUDI ARABIA LYSOSOMAL DISEASE TREATMENT MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 96. SOUTH AFRICA LYSOSOMAL DISEASE TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 97. SOUTH AFRICA LYSOSOMAL DISEASE TREATMENT MARKET, BY TYPE OF THERAPY, 2021-2031 ($MILLION)
TABLE 98. SOUTH AFRICA LYSOSOMAL DISEASE TREATMENT MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 99. REST OF LAMEA LYSOSOMAL DISEASE TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 100. REST OF LAMEA LYSOSOMAL DISEASE TREATMENT MARKET, BY TYPE OF THERAPY, 2021-2031 ($MILLION)
TABLE 101. REST OF LAMEA LYSOSOMAL DISEASE TREATMENT MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 102.AMICUS THERAPEUTICS, INC.: COMPANY SNAPSHOT
TABLE 103.AMICUS THERAPEUTICS, INC.: OPERATING SEGMENTS
TABLE 104.AMICUS THERAPEUTICS, INC.: PRODUCT PORTFOLIO
TABLE 105.AMICUS THERAPEUTICS, INC.: NET SALES,
TABLE 106.AMICUS THERAPEUTICS, INC.: KEY STRATERGIES
TABLE 107.ALEXION PHARMACEUTICALS, INC: COMPANY SNAPSHOT
TABLE 108.ALEXION PHARMACEUTICALS, INC: OPERATING SEGMENTS
TABLE 109.ALEXION PHARMACEUTICALS, INC: PRODUCT PORTFOLIO
TABLE 110.ALEXION PHARMACEUTICALS, INC: NET SALES,
TABLE 111.ALEXION PHARMACEUTICALS, INC: KEY STRATERGIES
TABLE 112.BIOMARIN: COMPANY SNAPSHOT
TABLE 113.BIOMARIN: OPERATING SEGMENTS
TABLE 114.BIOMARIN: PRODUCT PORTFOLIO
TABLE 115.BIOMARIN: NET SALES,
TABLE 116.BIOMARIN: KEY STRATERGIES
TABLE 117.JOHNSON & JOHNSON: COMPANY SNAPSHOT
TABLE 118.JOHNSON & JOHNSON: OPERATING SEGMENTS
TABLE 119.JOHNSON & JOHNSON: PRODUCT PORTFOLIO
TABLE 120.JOHNSON & JOHNSON: NET SALES,
TABLE 121.JOHNSON & JOHNSON: KEY STRATERGIES
TABLE 122.NOVARTIS AG: COMPANY SNAPSHOT
TABLE 123.NOVARTIS AG: OPERATING SEGMENTS
TABLE 124.NOVARTIS AG: PRODUCT PORTFOLIO
TABLE 125.NOVARTIS AG: NET SALES,
TABLE 126.NOVARTIS AG: KEY STRATERGIES
TABLE 127.PFIZER INC.: COMPANY SNAPSHOT
TABLE 128.PFIZER INC.: OPERATING SEGMENTS
TABLE 129.PFIZER INC.: PRODUCT PORTFOLIO
TABLE 130.PFIZER INC.: NET SALES,
TABLE 131.PFIZER INC.: KEY STRATERGIES
TABLE 132.SANOFI: COMPANY SNAPSHOT
TABLE 133.SANOFI: OPERATING SEGMENTS
TABLE 134.SANOFI: PRODUCT PORTFOLIO
TABLE 135.SANOFI: NET SALES,
TABLE 136.SANOFI: KEY STRATERGIES
TABLE 137.TAKEDA PHARMACEUTICAL COMPANY LIMITED: COMPANY SNAPSHOT
TABLE 138.TAKEDA PHARMACEUTICAL COMPANY LIMITED: OPERATING SEGMENTS
TABLE 139.TAKEDA PHARMACEUTICAL COMPANY LIMITED: PRODUCT PORTFOLIO
TABLE 140.TAKEDA PHARMACEUTICAL COMPANY LIMITED: NET SALES,
TABLE 141.TAKEDA PHARMACEUTICAL COMPANY LIMITED: KEY STRATERGIES
TABLE 142.ELI LILLY AND COMPANY: COMPANY SNAPSHOT
TABLE 143.ELI LILLY AND COMPANY: OPERATING SEGMENTS
TABLE 144.ELI LILLY AND COMPANY: PRODUCT PORTFOLIO
TABLE 145.ELI LILLY AND COMPANY: NET SALES,
TABLE 146.ELI LILLY AND COMPANY: KEY STRATERGIES
TABLE 147.SIGILON THERAPEUTICS, INC: COMPANY SNAPSHOT
TABLE 148.SIGILON THERAPEUTICS, INC: OPERATING SEGMENTS
TABLE 149.SIGILON THERAPEUTICS, INC: PRODUCT PORTFOLIO
TABLE 150.SIGILON THERAPEUTICS, INC: NET SALES,
TABLE 151.SIGILON THERAPEUTICS, INC: KEY STRATERGIES

LIST OF FIGURES

FIGURE 1.LYSOSOMAL DISEASE TREATMENT MARKET SEGMENTATION
FIGURE 2.LYSOSOMAL DISEASE TREATMENT MARKET,2021-2031
FIGURE 3.LYSOSOMAL DISEASE TREATMENT MARKET,2021-2031
FIGURE 4. TOP INVESTMENT POCKETS, BY REGION
FIGURE 5.PORTER FIVE-1
FIGURE 6.PORTER FIVE-2
FIGURE 7.PORTER FIVE-3
FIGURE 8.PORTER FIVE-4
FIGURE 9.PORTER FIVE-5
FIGURE 10.TOP PLAYER POSITIONING
FIGURE 11.LYSOSOMAL DISEASE TREATMENT MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
FIGURE 12.LYSOSOMAL DISEASE TREATMENT MARKET,BY DISEASE TYPE,2021(%)
FIGURE 13.COMPARATIVE SHARE ANALYSIS OF GAUCHER'S DISEASES LYSOSOMAL DISEASE TREATMENT MARKET,2021-2031(%)
FIGURE 14.COMPARATIVE SHARE ANALYSIS OF FABRY DISEASES LYSOSOMAL DISEASE TREATMENT MARKET,2021-2031(%)
FIGURE 15.COMPARATIVE SHARE ANALYSIS OF POMPE'S SYNDROME LYSOSOMAL DISEASE TREATMENT MARKET,2021-2031(%)
FIGURE 16.COMPARATIVE SHARE ANALYSIS OF MUCOPOLYSACCHARIDOSIS LYSOSOMAL DISEASE TREATMENT MARKET,2021-2031(%)
FIGURE 17.COMPARATIVE SHARE ANALYSIS OF OTHERS LYSOSOMAL DISEASE TREATMENT MARKET,2021-2031(%)
FIGURE 18.LYSOSOMAL DISEASE TREATMENT MARKET,BY TYPE OF THERAPY,2021(%)
FIGURE 19.COMPARATIVE SHARE ANALYSIS OF ENZYME REPLACEMENT THERAPY LYSOSOMAL DISEASE TREATMENT MARKET,2021-2031(%)
FIGURE 20.COMPARATIVE SHARE ANALYSIS OF STEM CELL THERAPY LYSOSOMAL DISEASE TREATMENT MARKET,2021-2031(%)
FIGURE 21.COMPARATIVE SHARE ANALYSIS OF SUBSTRATE REDUCTION THERAPY LYSOSOMAL DISEASE TREATMENT MARKET,2021-2031(%)
FIGURE 22.COMPARATIVE SHARE ANALYSIS OF OTHERS LYSOSOMAL DISEASE TREATMENT MARKET,2021-2031(%)
FIGURE 23.LYSOSOMAL DISEASE TREATMENT MARKET,BY END USER,2021(%)
FIGURE 24.COMPARATIVE SHARE ANALYSIS OF HOSPITALS LYSOSOMAL DISEASE TREATMENT MARKET,2021-2031(%)
FIGURE 25.COMPARATIVE SHARE ANALYSIS OF CLINICS LYSOSOMAL DISEASE TREATMENT MARKET,2021-2031(%)
FIGURE 26.COMPARATIVE SHARE ANALYSIS OF OTHERS LYSOSOMAL DISEASE TREATMENT MARKET,2021-2031(%)
FIGURE 27.LYSOSOMAL DISEASE TREATMENT MARKET BY REGION,2021
FIGURE 28.U.S. LYSOSOMAL DISEASE TREATMENT MARKET,2021-2031($MILLION)
FIGURE 29.CANADA LYSOSOMAL DISEASE TREATMENT MARKET,2021-2031($MILLION)
FIGURE 30.MEXICO LYSOSOMAL DISEASE TREATMENT MARKET,2021-2031($MILLION)
FIGURE 31.GERMANY LYSOSOMAL DISEASE TREATMENT MARKET,2021-2031($MILLION)
FIGURE 32.FRANCE LYSOSOMAL DISEASE TREATMENT MARKET,2021-2031($MILLION)
FIGURE 33.U.K. LYSOSOMAL DISEASE TREATMENT MARKET,2021-2031($MILLION)
FIGURE 34.ITALY LYSOSOMAL DISEASE TREATMENT MARKET,2021-2031($MILLION)
FIGURE 35.SPAIN LYSOSOMAL DISEASE TREATMENT MARKET,2021-2031($MILLION)
FIGURE 36.REST OF EUROPE LYSOSOMAL DISEASE TREATMENT MARKET,2021-2031($MILLION)
FIGURE 37.JAPAN LYSOSOMAL DISEASE TREATMENT MARKET,2021-2031($MILLION)
FIGURE 38.CHINA LYSOSOMAL DISEASE TREATMENT MARKET,2021-2031($MILLION)
FIGURE 39.AUSTRALIA LYSOSOMAL DISEASE TREATMENT MARKET,2021-2031($MILLION)
FIGURE 40.INDIA LYSOSOMAL DISEASE TREATMENT MARKET,2021-2031($MILLION)
FIGURE 41.SOUTH KOREA LYSOSOMAL DISEASE TREATMENT MARKET,2021-2031($MILLION)
FIGURE 42.REST OF ASIA-PACIFIC LYSOSOMAL DISEASE TREATMENT MARKET,2021-2031($MILLION)
FIGURE 43.BRAZIL LYSOSOMAL DISEASE TREATMENT MARKET,2021-2031($MILLION)
FIGURE 44.SAUDI ARABIA LYSOSOMAL DISEASE TREATMENT MARKET,2021-2031($MILLION)
FIGURE 45.SOUTH AFRICA LYSOSOMAL DISEASE TREATMENT MARKET,2021-2031($MILLION)
FIGURE 46.REST OF LAMEA LYSOSOMAL DISEASE TREATMENT MARKET,2021-2031($MILLION)
FIGURE 47. TOP WINNING STRATEGIES, BY YEAR
FIGURE 48. TOP WINNING STRATEGIES, BY DEVELOPMENT
FIGURE 49. TOP WINNING STRATEGIES, BY COMPANY
FIGURE 50.PRODUCT MAPPING OF TOP 10 PLAYERS
FIGURE 51.COMPETITIVE DASHBOARD
FIGURE 52.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS
FIGURE 53.AMICUS THERAPEUTICS, INC..: NET SALES ,($MILLION)
FIGURE 54.ALEXION PHARMACEUTICALS, INC.: NET SALES ,($MILLION)
FIGURE 55.BIOMARIN.: NET SALES ,($MILLION)
FIGURE 56.JOHNSON & JOHNSON.: NET SALES ,($MILLION)
FIGURE 57.NOVARTIS AG.: NET SALES ,($MILLION)
FIGURE 58.PFIZER INC..: NET SALES ,($MILLION)
FIGURE 59.SANOFI.: NET SALES ,($MILLION)
FIGURE 60.TAKEDA PHARMACEUTICAL COMPANY LIMITED.: NET SALES ,($MILLION)
FIGURE 61.ELI LILLY AND COMPANY.: NET SALES ,($MILLION)
FIGURE 62.SIGILON THERAPEUTICS, INC.: NET SALES ,($MILLION)

Product Code: A05290

The global lysosomal disease treatment market was valued at $7,572.97 million in 2021, and is projected to reach $14,090.39 million by 2031, registering a CAGR of 6.4% from 2022 to 2031.

Lysosomal disease is caused due to deficiency or absence of lysosomal acid lipase enzyme. The deficiency causes structural abnormalities of lysosome, result in storage of several toxic substances in the body cells. There are about 50 different types of these illnesses, which can harm heart, brain, skin, skeleton, and central nervous system among other physical organs. More lysosomal diseases are continuously being identified. Many lysosomal diseases currently lack an approved drug, despite the fact that clinical trials for prospective therapies for some of these disorders are now in progress.

A set of inherited metabolic diseases known as lysosomal storage disorders are brought on by enzyme deficits in different body cells. Key driver for growth of the global lysosomal disease treatment market includes increasing diagnosis rate, owing to increase in awareness and financial incentives for orphan drug development, which treats lysosomal diseases. In addition, rise in prevalence of lysosomal diseases, affordable product cost, increase in pharmaceutical companies for development of novel medications to treat lysosomal diseases are also responsible for growth of the market. Lack of treatment for lysosomal diseases and high cost of treatments are the factors that restrain growth of the market.

The lysosomal disease treatment market is segmented on the basis of disease type, type of therapy, end user, and region. By disease type, the market is divided into Gaucher's diseases, Fabry diseases, Pompe's syndrome, Mucopolysaccharidosis, and others. The others segment is further classified into aspartylglucosaminuria, batten disease, cystinosis, and glycogen storage disease II. By type of therapy, the market is fragmented into Enzyme replacement therapy, Stem cell therapy, Substrate reduction therapy, and others. By end user, it is segmented into Hospitals, Clinics, and others. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Major key players that operate in the global lysosomal disease treatment market include Amicus Therapeutics, Inc, Alexion Pharmaceuticals, Inc, BioMari, Chiese Farmaceutici SpA, Eli Lilly Company, Horizon Therapeutics Plc, Johnson & Johnson (Actelion Pharmaceuticals Ltd), Leadient Biosciences, Inc Novartis AG, Orphazyme A/S, Pfizer Inc, Recordati SpA, Sanofi (Genzyme Corporation), Sigilon Therapeutics, Inc, and Takeda Pharmaceutical Company Limited (Shire Plc) Valerion Therapeutics, Llc, and Viatris Inc (Mylan NV).

Key Benefits For Stakeholders

This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the lysosomal disease treatment market analysis from 2021 to 2031 to identify the prevailing lysosomal disease treatment market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the lysosomal disease treatment market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global lysosomal disease treatment market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Disease Type

Gaucher's Diseases
Fabry Diseases
Pompe's Syndrome
Mucopolysaccharidosis
Others

By Type of Therapy

Enzyme Replacement Therapy
Stem Cell Therapy
Substrate Reduction Therapy
Others

By End User

Hospitals
Clinics
Others

By Region

North America
- U.S.
- Canada
- Mexico
Europe
- Germany
- France
- U.K.
- Italy
- Spain
- Rest of Europe
Asia-Pacific
- Japan
- China
- Australia
- India
- South Korea
- Rest of Asia-Pacific
LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
Key Market Players
- Amicus Therapeutics, Inc.
- Alexion Pharmaceuticals, Inc
- BioMarin
- Johnson & Johnson
- Novartis AG
- Pfizer Inc.
- Sanofi
- Takeda Pharmaceutical Company Limited
- Eli Lilly and Company
- Sigilon Therapeutics, Inc

CHAPTER 1:INTRODUCTION

1.1.Report description
1.2.Key market segments
1.3.Key benefits to the stakeholders
1.4.Research Methodology
- 1.4.1.Secondary research
- 1.4.2.Primary research
- 1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

2.1.Key findings of the study
2.2.CXO Perspective

CHAPTER 3:MARKET OVERVIEW

3.1.Market definition and scope
3.2.Key findings
- 3.2.1.Top investment pockets
3.3.Porter's five forces analysis
3.4.Top player positioning
3.5.Market dynamics
- 3.5.1.Drivers
- 3.5.2.Restraints
- 3.5.3.Opportunities
3.6.COVID-19 Impact Analysis on the market

CHAPTER 4: LYSOSOMAL DISEASE TREATMENT MARKET, BY DISEASE TYPE

4.1 Overview
- 4.1.1 Market size and forecast
4.2 Gaucher's Diseases
- 4.2.1 Key market trends, growth factors and opportunities
- 4.2.2 Market size and forecast, by region
- 4.2.3 Market analysis by country
4.3 Fabry Diseases
- 4.3.1 Key market trends, growth factors and opportunities
- 4.3.2 Market size and forecast, by region
- 4.3.3 Market analysis by country
4.4 Pompe's Syndrome
- 4.4.1 Key market trends, growth factors and opportunities
- 4.4.2 Market size and forecast, by region
- 4.4.3 Market analysis by country
4.5 Mucopolysaccharidosis
- 4.5.1 Key market trends, growth factors and opportunities
- 4.5.2 Market size and forecast, by region
- 4.5.3 Market analysis by country
4.6 Others
- 4.6.1 Key market trends, growth factors and opportunities
- 4.6.2 Market size and forecast, by region
- 4.6.3 Market analysis by country

CHAPTER 5: LYSOSOMAL DISEASE TREATMENT MARKET, BY TYPE OF THERAPY

5.1 Overview
- 5.1.1 Market size and forecast
5.2 Enzyme Replacement Therapy
- 5.2.1 Key market trends, growth factors and opportunities
- 5.2.2 Market size and forecast, by region
- 5.2.3 Market analysis by country
5.3 Stem Cell Therapy
- 5.3.1 Key market trends, growth factors and opportunities
- 5.3.2 Market size and forecast, by region
- 5.3.3 Market analysis by country
5.4 Substrate Reduction Therapy
- 5.4.1 Key market trends, growth factors and opportunities
- 5.4.2 Market size and forecast, by region
- 5.4.3 Market analysis by country
5.5 Others
- 5.5.1 Key market trends, growth factors and opportunities
- 5.5.2 Market size and forecast, by region
- 5.5.3 Market analysis by country

CHAPTER 6: LYSOSOMAL DISEASE TREATMENT MARKET, BY END USER

6.1 Overview
- 6.1.1 Market size and forecast
6.2 Hospitals
- 6.2.1 Key market trends, growth factors and opportunities
- 6.2.2 Market size and forecast, by region
- 6.2.3 Market analysis by country
6.3 Clinics
- 6.3.1 Key market trends, growth factors and opportunities
- 6.3.2 Market size and forecast, by region
- 6.3.3 Market analysis by country
6.4 Others
- 6.4.1 Key market trends, growth factors and opportunities
- 6.4.2 Market size and forecast, by region
- 6.4.3 Market analysis by country

CHAPTER 7: LYSOSOMAL DISEASE TREATMENT MARKET, BY REGION

7.1 Overview
- 7.1.1 Market size and forecast
7.2 North America
- 7.2.1 Key trends and opportunities
- 7.2.2 North America Market size and forecast, by Disease Type
- 7.2.3 North America Market size and forecast, by Type of Therapy
- 7.2.4 North America Market size and forecast, by End User
- 7.2.5 North America Market size and forecast, by country
  - 7.2.5.1 U.S.
  - 7.2.5.1.1 Market size and forecast, by Disease Type
  - 7.2.5.1.2 Market size and forecast, by Type of Therapy
  - 7.2.5.1.3 Market size and forecast, by End User
  - 7.2.5.2 Canada
  - 7.2.5.2.1 Market size and forecast, by Disease Type
  - 7.2.5.2.2 Market size and forecast, by Type of Therapy
  - 7.2.5.2.3 Market size and forecast, by End User
  - 7.2.5.3 Mexico
  - 7.2.5.3.1 Market size and forecast, by Disease Type
  - 7.2.5.3.2 Market size and forecast, by Type of Therapy
  - 7.2.5.3.3 Market size and forecast, by End User
7.3 Europe
- 7.3.1 Key trends and opportunities
- 7.3.2 Europe Market size and forecast, by Disease Type
- 7.3.3 Europe Market size and forecast, by Type of Therapy
- 7.3.4 Europe Market size and forecast, by End User
- 7.3.5 Europe Market size and forecast, by country
  - 7.3.5.1 Germany
  - 7.3.5.1.1 Market size and forecast, by Disease Type
  - 7.3.5.1.2 Market size and forecast, by Type of Therapy
  - 7.3.5.1.3 Market size and forecast, by End User
  - 7.3.5.2 France
  - 7.3.5.2.1 Market size and forecast, by Disease Type
  - 7.3.5.2.2 Market size and forecast, by Type of Therapy
  - 7.3.5.2.3 Market size and forecast, by End User
  - 7.3.5.3 U.K.
  - 7.3.5.3.1 Market size and forecast, by Disease Type
  - 7.3.5.3.2 Market size and forecast, by Type of Therapy
  - 7.3.5.3.3 Market size and forecast, by End User
  - 7.3.5.4 Italy
  - 7.3.5.4.1 Market size and forecast, by Disease Type
  - 7.3.5.4.2 Market size and forecast, by Type of Therapy
  - 7.3.5.4.3 Market size and forecast, by End User
  - 7.3.5.5 Spain
  - 7.3.5.5.1 Market size and forecast, by Disease Type
  - 7.3.5.5.2 Market size and forecast, by Type of Therapy
  - 7.3.5.5.3 Market size and forecast, by End User
  - 7.3.5.6 Rest of Europe
  - 7.3.5.6.1 Market size and forecast, by Disease Type
  - 7.3.5.6.2 Market size and forecast, by Type of Therapy
  - 7.3.5.6.3 Market size and forecast, by End User
7.4 Asia-Pacific
- 7.4.1 Key trends and opportunities
- 7.4.2 Asia-Pacific Market size and forecast, by Disease Type
- 7.4.3 Asia-Pacific Market size and forecast, by Type of Therapy
- 7.4.4 Asia-Pacific Market size and forecast, by End User
- 7.4.5 Asia-Pacific Market size and forecast, by country
  - 7.4.5.1 Japan
  - 7.4.5.1.1 Market size and forecast, by Disease Type
  - 7.4.5.1.2 Market size and forecast, by Type of Therapy
  - 7.4.5.1.3 Market size and forecast, by End User
  - 7.4.5.2 China
  - 7.4.5.2.1 Market size and forecast, by Disease Type
  - 7.4.5.2.2 Market size and forecast, by Type of Therapy
  - 7.4.5.2.3 Market size and forecast, by End User
  - 7.4.5.3 Australia
  - 7.4.5.3.1 Market size and forecast, by Disease Type
  - 7.4.5.3.2 Market size and forecast, by Type of Therapy
  - 7.4.5.3.3 Market size and forecast, by End User
  - 7.4.5.4 India
  - 7.4.5.4.1 Market size and forecast, by Disease Type
  - 7.4.5.4.2 Market size and forecast, by Type of Therapy
  - 7.4.5.4.3 Market size and forecast, by End User
  - 7.4.5.5 South Korea
  - 7.4.5.5.1 Market size and forecast, by Disease Type
  - 7.4.5.5.2 Market size and forecast, by Type of Therapy
  - 7.4.5.5.3 Market size and forecast, by End User
  - 7.4.5.6 Rest of Asia-Pacific
  - 7.4.5.6.1 Market size and forecast, by Disease Type
  - 7.4.5.6.2 Market size and forecast, by Type of Therapy
  - 7.4.5.6.3 Market size and forecast, by End User
7.5 LAMEA
- 7.5.1 Key trends and opportunities
- 7.5.2 LAMEA Market size and forecast, by Disease Type
- 7.5.3 LAMEA Market size and forecast, by Type of Therapy
- 7.5.4 LAMEA Market size and forecast, by End User
- 7.5.5 LAMEA Market size and forecast, by country
  - 7.5.5.1 Brazil
  - 7.5.5.1.1 Market size and forecast, by Disease Type
  - 7.5.5.1.2 Market size and forecast, by Type of Therapy
  - 7.5.5.1.3 Market size and forecast, by End User
  - 7.5.5.2 Saudi Arabia
  - 7.5.5.2.1 Market size and forecast, by Disease Type
  - 7.5.5.2.2 Market size and forecast, by Type of Therapy
  - 7.5.5.2.3 Market size and forecast, by End User
  - 7.5.5.3 South Africa
  - 7.5.5.3.1 Market size and forecast, by Disease Type
  - 7.5.5.3.2 Market size and forecast, by Type of Therapy
  - 7.5.5.3.3 Market size and forecast, by End User
  - 7.5.5.4 Rest of LAMEA
  - 7.5.5.4.1 Market size and forecast, by Disease Type
  - 7.5.5.4.2 Market size and forecast, by Type of Therapy
  - 7.5.5.4.3 Market size and forecast, by End User

CHAPTER 8: COMPANY LANDSCAPE

8.1. Introduction
8.2. Top winning strategies
8.3. Product Mapping of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Key developments

CHAPTER 9: COMPANY PROFILES

9.1 Amicus Therapeutics, Inc.
- 9.1.1 Company overview
- 9.1.2 Company snapshot
- 9.1.3 Operating business segments
- 9.1.4 Product portfolio
- 9.1.5 Business performance
- 9.1.6 Key strategic moves and developments
9.2 Alexion Pharmaceuticals, Inc
- 9.2.1 Company overview
- 9.2.2 Company snapshot
- 9.2.3 Operating business segments
- 9.2.4 Product portfolio
- 9.2.5 Business performance
- 9.2.6 Key strategic moves and developments
9.3 BioMarin
- 9.3.1 Company overview
- 9.3.2 Company snapshot
- 9.3.3 Operating business segments
- 9.3.4 Product portfolio
- 9.3.5 Business performance
- 9.3.6 Key strategic moves and developments
9.4 Johnson & Johnson
- 9.4.1 Company overview
- 9.4.2 Company snapshot
- 9.4.3 Operating business segments
- 9.4.4 Product portfolio
- 9.4.5 Business performance
- 9.4.6 Key strategic moves and developments
9.5 Novartis AG
- 9.5.1 Company overview
- 9.5.2 Company snapshot
- 9.5.3 Operating business segments
- 9.5.4 Product portfolio
- 9.5.5 Business performance
- 9.5.6 Key strategic moves and developments
9.6 Pfizer Inc.
- 9.6.1 Company overview
- 9.6.2 Company snapshot
- 9.6.3 Operating business segments
- 9.6.4 Product portfolio
- 9.6.5 Business performance
- 9.6.6 Key strategic moves and developments
9.7 Sanofi
- 9.7.1 Company overview
- 9.7.2 Company snapshot
- 9.7.3 Operating business segments
- 9.7.4 Product portfolio
- 9.7.5 Business performance
- 9.7.6 Key strategic moves and developments
9.8 Takeda Pharmaceutical Company Limited
- 9.8.1 Company overview
- 9.8.2 Company snapshot
- 9.8.3 Operating business segments
- 9.8.4 Product portfolio
- 9.8.5 Business performance
- 9.8.6 Key strategic moves and developments
9.9 Eli Lilly and Company
- 9.9.1 Company overview
- 9.9.2 Company snapshot
- 9.9.3 Operating business segments
- 9.9.4 Product portfolio
- 9.9.5 Business performance
- 9.9.6 Key strategic moves and developments
9.10 Sigilon Therapeutics, Inc
- 9.10.1 Company overview
- 9.10.2 Company snapshot
- 9.10.3 Operating business segments
- 9.10.4 Product portfolio
- 9.10.5 Business performance
- 9.10.6 Key strategic moves and developments

ライソゾーム病治療市場：疾患タイプ別、治療タイプ別、エンドユーザー別：世界の機会分析および産業予測、2021-2031年

Lysosomal Disease Treatment Market By Disease Type, By Type of Therapy, By End User : Global Opportunity Analysis and Industry Forecast, 2021-2031

目次

第1章イントロダクション

第2章エグゼクティブサマリー

第3章市場の概要

第4章ライソゾーム病治療市場：疾患タイプ別

第5章ライソゾーム病治療市場：治療法タイプ別

第6章ライソゾーム病治療市場：エンドユーザー別

第7章ライソゾーム病治療市場：地域別

第8章企業情勢

第9章企業プロファイル

LIST OF TABLES

LIST OF FIGURES

TABLE OF CONTENTS

CHAPTER 1:INTRODUCTION

CHAPTER 2:EXECUTIVE SUMMARY

CHAPTER 3:MARKET OVERVIEW

CHAPTER 4: LYSOSOMAL DISEASE TREATMENT MARKET, BY DISEASE TYPE

CHAPTER 5: LYSOSOMAL DISEASE TREATMENT MARKET, BY TYPE OF THERAPY

CHAPTER 6: LYSOSOMAL DISEASE TREATMENT MARKET, BY END USER

CHAPTER 7: LYSOSOMAL DISEASE TREATMENT MARKET, BY REGION

CHAPTER 8: COMPANY LANDSCAPE

CHAPTER 9: COMPANY PROFILES

ライソゾーム病治療市場：疾患タイプ別、治療タイプ別、エンドユーザー別：世界の機会分析および産業予測、2021-2031年

Lysosomal Disease Treatment Market By Disease Type, By Type of Therapy, By End User : Global Opportunity Analysis and Industry Forecast, 2021-2031

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 市場の概要

第4章 ライソゾーム病治療市場：疾患タイプ別

第5章 ライソゾーム病治療市場：治療法タイプ別

第6章 ライソゾーム病治療市場：エンドユーザー別

第7章 ライソゾーム病治療市場： 地域別

第8章 企業情勢

第9章 企業プロファイル

LIST OF TABLES

LIST OF FIGURES

TABLE OF CONTENTS

CHAPTER 1:INTRODUCTION

CHAPTER 2:EXECUTIVE SUMMARY

CHAPTER 3:MARKET OVERVIEW

CHAPTER 4: LYSOSOMAL DISEASE TREATMENT MARKET, BY DISEASE TYPE

CHAPTER 5: LYSOSOMAL DISEASE TREATMENT MARKET, BY TYPE OF THERAPY

CHAPTER 6: LYSOSOMAL DISEASE TREATMENT MARKET, BY END USER

CHAPTER 7: LYSOSOMAL DISEASE TREATMENT MARKET, BY REGION

CHAPTER 8: COMPANY LANDSCAPE

CHAPTER 9: COMPANY PROFILES

第1章イントロダクション

第2章エグゼクティブサマリー

第3章市場の概要

第4章ライソゾーム病治療市場：疾患タイプ別

第5章ライソゾーム病治療市場：治療法タイプ別

第6章ライソゾーム病治療市場：エンドユーザー別

第7章ライソゾーム病治療市場：地域別

第8章企業情勢

第9章企業プロファイル